ALEXANDRIA, Va., Sept. 29 /PRNewswire-USNewswire/ -- The National Community Pharmacists Association (NCPA) expressed strong support for an investigation into CVS Caremark launched by the U.S. Senate Special Committee on Aging reported earlier today on the blog Pharmalot.
In response, NCPA President Joseph H. Harmison, PD and Arlington, Texas pharmacy owner, issued the following statement:
"Complaints continue to increase from patients and community pharmacists alleging CVS Caremark of engaging in anti-consumer, anti-competitive behavior. We commend Chairman Herb Kohl (D-Wisc.) for doing the right thing on behalf of patients and pharmacists in Wisconsin and across the nation. Seniors are both the most in need of pharmacy services and the patients arguably most vulnerable to the misleading and deceptive tactics of which CVS Caremark is accused.
"CVS Caremark's strong-armed efforts to gain market share appear to be compromising patient care while inflating costs for seniors, the Medicare program and taxpayers. For example, retirees Max and Jan Hauser discovered that, under their Medicare drug plan administered by CVS Caremark, the cholesterol drug Simvastatin that cost them nothing at a local independent pharmacy cost them $165.99 at CVS for a three-month supply. As reported by WCNC-TV they were also charged more by CVS for ulcer drugs and blood